Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Long-Term Debt Repayments (2021 - 2024)

Seres Therapeutics (MCRB) has disclosed Long-Term Debt Repayments for 5 consecutive years, with $127.9 million as the latest value for Q3 2024.

  • Quarterly Long-Term Debt Repayments changed N/A to $127.9 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $127.9 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $127.9 million for FY2024, 141.97% up from the prior year.
  • Long-Term Debt Repayments hit $127.9 million in Q3 2024 for Seres Therapeutics, up from $52.9 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $127.9 million in Q3 2024 to a low of $948000.0 in Q4 2021.
  • Historically, Long-Term Debt Repayments has averaged $45.9 million across 4 years, with a median of $27.4 million in 2022.